Altimmune Future Growth

Future criteria checks 2/6

Altimmune is forecast to grow earnings and revenue by 20.2% and 71.5% per annum respectively while EPS is expected to grow by 29.5% per annum.

Key information

20.2%

Earnings growth rate

29.5%

EPS growth rate

Biotechs earnings growth37.8%
Revenue growth rate71.5%
Future return on equityn/a
Analyst coverage

Good

Last updated04 Nov 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

LSE:0A4C - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026N/A-173-172-907
12/31/202525-137-92-778
12/31/202431-59-77438
6/30/20240-101-71-71N/A
3/31/20240-93-73-73N/A
12/31/20230-88-76-76N/A
9/30/20230-78-77-77N/A
6/30/20230-81-71-71N/A
3/31/20230-85-69-68N/A
12/31/20220-85-63-63N/A
9/30/20223-87-67-67N/A
6/30/20223-97-70-70N/A
3/31/20224-102-80-72N/A
12/31/20214-97-91-78N/A
9/30/20213-84-82-70N/A
6/30/20216-68-74-61N/A
3/31/20217-60-54-50N/A
12/31/20208-49-35-34N/A
9/30/20206-43-23-23N/A
6/30/20204-36-16-16N/A
3/31/20205-22-12-12N/A
12/31/20196-21-10-10N/A
9/30/20198-42-13-13N/A
6/30/201910-34-12-11N/A
3/31/201911-40-8-8N/A
12/31/201810-42-10-9N/A
9/30/201811-29-10-9N/A
6/30/201813-58-13-12N/A
3/31/201813-52N/A-20N/A
12/31/201711-51N/A-20N/A
9/30/20179-43N/A-17N/A
6/30/20175-16N/A-15N/A
3/31/20173-14N/A-8N/A
12/31/20163-11N/A-6N/A
9/30/20163-10N/A-7N/A
12/31/20155-7N/A-5N/A
12/31/20146-1N/A0N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 0A4C is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 0A4C is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 0A4C is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 0A4C's revenue (71.5% per year) is forecast to grow faster than the UK market (3.6% per year).

High Growth Revenue: 0A4C's revenue (71.5% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 0A4C's Return on Equity is forecast to be high in 3 years time


Discover growth companies